Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double-Blind Placebo-Controlled Trial

Prolonged thrombocytopenia occurs in up to 37% of patients after hematopoietic stem cell transplantation (HSCT) and is associated with adverse prognosis and increased risk of bleeding. Eltrombopag, a thrombopoietin receptor agonist, can increase platelet counts in thrombocytopenic patients. We conducted a phase II study, adaptively randomizing patients ≥35 days post-HSCT to receive placebo or eltrombopag if platelet count ≤ 20,000/µL for seven days or platelet transfusion-dependent, and neutrophil count ≥ 1500/µL.

Source: Biology of Blood and Marrow Transplantation - February 5, 2021 Category: Hematology Authors: Sairah Ahmed, Qaiser Bashir, Roland Bassett, Man-Yin C. Poon, Ben Valdez, Sergej Konoplev, Amin M. Alousi, Borje S. Andersson, Stefan Ciurea, Chitra Hosing, Roy Jones, Partow Kebriaei, Issa Khouri, Stella Kim, Yago Nieto, Amanda Olson, Betul Oran, Simrit Source Type: research